Core Viewpoint - Boston Scientific (BSX) is showing potential as a stock pick due to its recent technical performance and positive earnings estimate revisions [1][3]. Technical Analysis - BSX has surpassed the 50-day moving average, indicating a short-term bullish trend [1]. - The stock has increased by 5.7% over the past four weeks, suggesting upward momentum [2]. Earnings Estimates - There have been no downward revisions for BSX's earnings estimates in the past two months, with one upward revision noted [3]. - The consensus estimate for BSX has also increased, reinforcing the bullish outlook for the stock [3]. Market Position - BSX is currently rated as a Zacks Rank 2 (Buy), indicating strong potential for continued growth [2].

Company Performance - Boston Scientific (BSX) closed at $97.79, with a gain of +2.42%, outperforming the S&P 500's gain of 0.62% on the same day [1] - Prior to this trading session, BSX shares had increased by 1.75%, contrasting with the Medical sector's decline of 1.22% and the S&P 500's gain of 0.59% [1] Earnings Projections - The company is expected to release its earnings on February 4, 2026, with projected EPS of $0.78, reflecting an 11.43% increase year-over-year [2] - Revenue for the upcoming quarter is anticipated to be $5.27 billion, indicating a 15.44% increase compared to the same quarter last year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $3.04 per share, representing a +21.12% change from the previous year, while revenue is estimated at $20.06 billion, showing no change [3] - Recent analyst estimate revisions for Boston Scientific suggest positive short-term business trends, which are typically seen as favorable for the business outlook [3] Stock Valuation - Boston Scientific is currently trading at a Forward P/E ratio of 27.65, which is higher than the industry average of 19.35 [6] - The company has a PEG ratio of 1.69, compared to the Medical - Products industry's average PEG ratio of 1.71 [6] Industry Ranking - The Medical - Products industry, part of the Medical sector, has a Zacks Industry Rank of 162, placing it in the bottom 34% of over 250 industries [7] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Group 1 - Boston Scientific Corporation will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, in San Francisco, with a 40-minute Q&A session featuring key executives [1] - The company will host a conference call on February 4, 2026, at 8:00 a.m. ET to discuss financial results for Q4 and the full year ended December 31, 2025 [2] - A news release announcing the financial results will be issued prior to the conference call on February 4 [2] Group 2 - Boston Scientific is a global medical technology leader with over 45 years of experience, focusing on innovative medical technologies that improve patient health [4] - The company's portfolio includes high-performance solutions for diagnosing and treating complex diseases across various medical fields, including cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions [4]

Core Insights - Boston Scientific's Cardiovascular segment operates in a $50 billion market, projected to grow nearly 9% from 2026 to 2028, with expectations to exceed 10% average organic revenue growth [1] - The Electrophysiology (EP) business is anticipated to grow approximately 15% over the long-range plan, driven by market share gains and expansion into new areas [1][8] - The WATCHMAN device is the leading percutaneous left atrial appendage closure (LAAC) device globally, with a long-term growth outlook of over 20% contingent on trial outcomes [2][8] - The CRM DX business is expected to grow about 4% over the long-range plan, supported by recent investments and new product launches [3] - The Interventional Cardiology Therapies (ICTx) segment is projected to achieve 10% growth, particularly in emerging markets [4][8] - The Peripheral Interventions, Interventional Oncology, and Embolics businesses collectively represent a $11 billion market, with expected growth around 7% [4] Competitive Landscape - Medtronic's Diabetes business is preparing for an IPO, while its Hugo robotic-assisted surgery system has received FDA approval for urologic procedures [5] - Johnson & Johnson has acquired Halda Therapeutics for $3.05 billion, enhancing its portfolio in prostate cancer therapies [6] Financial Performance - Boston Scientific shares have increased by 7.5% over the past year, outperforming the industry average of 1.7% [7] - The company's forward five-year Price-to-Earnings (P/E) ratio stands at 27.81, above both its median and the industry average [9] Earnings Estimates - Current earnings estimates for Boston Scientific indicate a projected earnings per share of $3.04 for the year ending December 2025, increasing to $3.45 for December 2026 [11]

Core Insights - Boston Scientific (BSX) and Resmed (RMD) are significant players in the global medical devices market, with market capitalizations of $142.4 billion and $35.72 billion, respectively [2] - The medical devices market is projected to grow at nearly 7% CAGR from 2025 to 2030, prompting an evaluation of investment opportunities in both companies [3] Boston Scientific Overview - Boston Scientific is experiencing strong performance in its Cardiovascular and MedSurg segments, with expectations for above-market growth through 2025-2026 [4] - The WATCHMAN device is a leading product in percutaneous left atrial appendage closure (LAAC), with a projected market expansion of approximately 20% in the coming years [5] - The company is gaining market share in electrophysiology, particularly with the FARAPULSE Pulsed Field Ablation System, which received FDA approval for expanded use in July 2025 [6] - Recent acquisitions, including Intera Oncology and Elutia's BioEnvelope business, support Boston Scientific's growth strategy and expansion into high-growth areas [7] - Emerging markets accounted for 15% of Boston Scientific's consolidated net sales in the first nine months of 2025, indicating significant long-term growth potential [8] Resmed Overview - Resmed is witnessing strong demand for its mask portfolio, including the AirFit and AirTouch ranges, and is focusing on direct-to-consumer markets in regions like China and India [9] - The company has launched new variants of its AirTouch F30i mask and continues to see strong sales from its AirSense device platforms [9] - Resmed is advancing AI integration in its digital health products, including the launch of the personal sleep health digital assistant, Dawn, in the U.S. [11] - The company is optimizing operations to improve gross margins and has made acquisitions like Somnoware and Ectosense to support its 2030 growth strategy [12] Financial Estimates and Performance - The Zacks Consensus Estimate for Boston Scientific's 2025 EPS indicates a year-over-year increase of 21.1% to $3.04, with a slight upward revision in the last 60 days [13] - Resmed's fiscal 2026 EPS consensus estimate of $10.84 reflects a 13.5% improvement over 2025, with a 3.3% increase in estimates over the past 60 days [15] - In the last 12 months, BSX shares have increased by 6.8%, while RMD shares have risen by 5.8% [16] Investment Considerations - Boston Scientific is highlighted for its divisional strength, ongoing momentum with the WATCHMAN device, and strategic acquisitions in high-growth markets [18] - Resmed remains focused on innovation and strong demand for its products, but Boston Scientific is currently viewed as the more attractive investment option based on recent performance [18] - Boston Scientific holds a Zacks Rank 2 (Buy), while Resmed has a Zacks Rank 3 (Hold) [20]

Core Viewpoint - Boston Scientific (BSX) is viewed positively for both short-term and long-term prospects, being considered one of the best investment ideas in the medical devices sector [1]. Company Analysis - The company operates within the medical devices industry, which is characterized by significant growth potential and innovation [1]. - Boston Scientific is recognized for its strong fundamentals and ability to uncover hidden value, making it an attractive option for investors [1]. Market Context - The medical devices sector is experiencing robust demand, driven by advancements in technology and an increasing focus on healthcare solutions [1]. - Investment opportunities in this sector are expected to grow, particularly for companies like Boston Scientific that demonstrate strong performance and strategic positioning [1].

Core Viewpoint - Boston Scientific (BSX) is viewed positively for both short-term and long-term investment prospects, being considered one of the best investment ideas in the medical devices sector [1]. Company Analysis - The company operates within the medical devices industry, which is characterized by significant growth potential and innovation [1]. - Boston Scientific is recognized for its strong fundamentals and ability to uncover hidden value, making it an attractive option for investors [1]. Market Context - The medical devices sector is experiencing robust demand, driven by advancements in technology and an increasing focus on healthcare solutions [1]. - Investment opportunities in this sector are expected to continue growing, positioning companies like Boston Scientific favorably in the market [1].

Core Insights - Hardman Johnston Global Advisors reported underperformance in its portfolio for Q3 2025, with a return of 5.02% net of fees, compared to 7.62% for the MSCI AC World Net Index [1] Company Overview - Boston Scientific Corporation (NYSE:BSX) is highlighted as a key stock in the investor letter, operating in the MedSurg and Cardiovascular segments of the medical device industry [2] - As of December 24, 2025, Boston Scientific's stock closed at $96.13 per share, with a market capitalization of $142.51 billion [2] Performance Analysis - Boston Scientific experienced a one-month return of -4.78% but gained 5.56% over the last 52 weeks [2] - The company was identified as a significant driver of underperformance within the healthcare sector, alongside Vertex Pharmaceuticals [3] Market Context - The Trump administration's Section 232 tariff investigation into medical devices has increased macroeconomic uncertainty, but Boston Scientific is well-positioned to manage potential tariffs due to its diverse supply chain and increased U.S. manufacturing footprint post-COVID [3] - The company has strong pricing power and has largely mitigated tariff impacts thus far [3] - The market is witnessing a rotation from medical devices to pharmaceuticals/biotech, influenced by recent deals such as the one between Pfizer and the Trump administration [3] Growth Prospects - Boston Scientific's diversified growth profile across various franchises, including cardiology, electrophysiology, endoscopy, and urology, supports a favorable outlook [3] - The introduction of Farapulse, a pulsed-field ablation technology, is expected to drive significant growth in the electrophysiology segment [3] - Management has set new long-term targets of 10% organic revenue growth, 50 basis points of annual margin expansion, and double-digit EPS growth through 2028, with a strong track record of exceeding previous targets [3]

Core Viewpoint - Boston Scientific is undergoing a planned management transition in its Cardiac Rhythm Management & Diagnostics (CRMDx) business, with Scott Olson retiring at the end of 2025 and Angelo De Rosa taking over in early 2026 [2][3][11]. Group 1: Management Transition - Scott Olson has served as the Senior Vice President and President of the CRMDx business for 27 years and will retire at the end of 2025 [5][7]. - Angelo De Rosa, who joined Boston Scientific in 2014, will assume the role of CRMDx business leader in 2026. He has previously led the Watchman left atrial appendage closure business [8][10]. Group 2: CRMDx Business Overview - The CRMDx business focuses on cardiac rhythm management and related diagnostic solutions, including pacemakers and implantable cardioverter-defibrillators (ICDs), and is a crucial part of Boston Scientific's cardiovascular device portfolio [4]. - This business addresses core clinical needs related to arrhythmias and has a stable market foundation and strategic position within the company's overall business structure [4]. Group 3: Leadership Insights - Olson emphasized the importance of teamwork and patient-centered values during his tenure and expressed gratitude for his long-term collaboration with the internal team [7]. - De Rosa views his transition to CRMDx as a return to his roots, having previously worked in the cardiac rhythm management field early in his career [10].

Core Viewpoint - Valuation may not be significant in the short term for well-managed companies with above-average growth, but it eventually becomes important, as evidenced by Boston Scientific Corporation in 2025 [1] Group 1 - The article emphasizes that valuation matters over time, particularly for companies like Boston Scientific Corporation [1]